PAVmed Q2 revenue jumps to $33k; $30m warrants issued
PAVmed Inc. reported Q2 2026 revenue of $33 thousand, a 450% increase year-over-year. The company issued $30 million in warrants and holds $3.8 million in cash. PortIO may pursue a faster 510(k) regulatory pathway.
*this image is generated using AI for illustrative purposes only.
PAVmed Inc. (NASDAQ: PAVM) reported second quarter 2026 revenue of $33 thousand, a significant increase from $6 thousand in the same period of 2025. In addition to operational progress across its subsidiaries, the company announced the elimination of Series D preferred stock and the issuance of $30 million in warrants convertible into common stock, pending positive EsoGuard LCD publication.
For the three months ended June 30, 2026, GAAP net loss attributable to common stockholders was $5.5 million, or $(0.87) per diluted share. On a non-GAAP basis, adjusted net loss narrowed to $1.7 million, or $(0.27) per share, excluding stock-based compensation and other non-cash items.
Financial Performance
Operating expenses for the quarter totaled approximately $7.1 million, including $0.9 million in stock-based compensation. Research and development expenses increased primarily due to Verus implantable device development, contributing to a rise in non-GAAP operating expenses to $6.1 million. The company recorded other income of $424 thousand, contrasting with an expense of $7.6 million in the prior year quarter.
| Metric: | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue: | $33 thousand | $6 thousand | +450% |
| Operating Expenses: | $7.1 million | $4.7 million | +50% |
| GAAP Net Loss: | $5.5 million | $13.3 million | -59% |
| Non-GAAP Adj. Loss: | $1.7 million | $0.8 million | +100% |
Cash and cash equivalents stood at $3.8 million as of June 30, 2026, up from $1.5 million as of December 31, 2025. This cash position does not include the expected $30 million from warrants and $2.5 million from Verus warrants contingent on FDA clearance. For the first half of 2026, revenue was $55 thousand compared to $14 thousand in H1 2025.
Business Updates
Veris Health accelerated its commercial engagement with OSU-The James, increasing patient onboarding across additional departments. The subsidiary is progressing its implantable physiological monitor toward an early 2027 FDA 510(k) submission, with design freeze nearing completion. Commercialization efforts are progressing with a target of enrolling 1,000 patients in a registry over a year, with two-thirds of departments now onboarding.
Lucid Diagnostics recognized $1.5 million in EsoGuard Esophageal DNA Test revenue for Q2 2026 and processed 2,770 tests. The company secured its first laboratory benefit manager coverage policy for EsoGuard, which has been adopted by multiple client health plans. PAVmed holds approximately 15% of Lucid Diagnostics, with significant influence despite not having voting control.
In the medical device portfolio, PortIO published first-in-human results demonstrating 100% device patency and no device-related adverse events. Management indicated that while previous engagement was firmly in the De Novo pathway, the company may be able to pursue a 510(k) pathway with existing short-term intraosseous devices as a predicate. This would significantly reduce cost and time if successful. An FDA pre-submission meeting is planned for the fourth quarter, potentially leaking into early 2027.
Octeris continued development of its multimodal endoscopic imaging probe, completing its FDA pre-submission draft. Clinical validation is underway, with several years anticipated before product commercialization. The license with Duke University for OCTaris technology includes worldwide rights.
What the Numbers Show
Revenue growth outpaced operating expense expansion on a percentage basis, though absolute costs remained high relative to top-line generation. Stock-based compensation of $0.9 million constituted roughly 13% of total operating expenses, highlighting the ongoing dilutive cost structure typical of development-stage biotech firms. The widening gap between GAAP and non-GAAP losses—driven largely by changes in fair value of equity method investments and convertible debt—underscores the volatility inherent in the company's financing instruments. The issuance of $30 million in warrants provides a potential capital infusion that could support the parallel console development work for Octeris, which management noted depends on access to capital.
How will the potential shift of PortIO from the De Novo to the 510(k) regulatory pathway impact the company's projected timeline for market entry and capital requirements?
Given the $30 million warrant issuance is contingent on the EsoGuard LCD publication, what are the specific risks if the publication results are unfavorable or delayed?
With only $3.8 million in cash on hand, how sustainable is PAVmed's current burn rate before the contingent capital from warrants and Verus FDA clearance is realized?
18
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
